Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

CONCLUSION: In a phase IIb study in RA, the safety and tolerability profile of baricitinib, up to 128 weeks, remained consistent with earlier observations, without unexpected late signals. Clinical improvements seen in the 24-week blinded period were maintained during the OLE. PMID: 28811354 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28811354?dopt=Abstract

Source: J Rheumatol - August 15, 2017 Category: Rheumatology Authors: Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC Tags: J Rheumatol Source Type: research